Malaria

Approximately half of the world population lives at risk of malaria

According to the 2017 World Malaria Report, 91 countires confirmed almost 216 million cases in 2016 (an increase of 5 million compared to the previous year).

In 2016, malaria killed more than 445,000 people. Fifteen countries accounted for 80% of global deaths; all of them except one are in Subsaharan Africa, where 9 out of 10 deaths occurred.

Main Lines of Research

Enabling technologies for malaria research
Parasite biology
Pathophysiology
Malaria immunology
Diagnostics
Evaluation of preventive and therapeutic tools
Epidemiology and clinical presentation of Plasmodium falciparum and Plasmodium vivax
Vector biology and control
Novel approaches and strategies for malaria elimination
Health economy studies and assessment of the economic impact of malaria elimination

Coordinator

Quique Bassat ICREA Research Professor

ISGlobal team

Azucena Bardají Assistant Research Professor
Carlos Chaccour BOHEMIA Chief Scientific Officer
Alfred Cortés ICREA Research Professor
Carlota Dobaño Associate Research Professor
Xavier Fernàndez Associate Research Professor
Carmen Fernández Assistant Research Professor
Raquel González Assistant Research Professor
Caterina Guinovart Senior Advisor for Research and Implementation on malaria elimination
Luis Izquierdo Associate Research Professor
Alfredo Mayor Associate Research Professor
Clara Menéndez Director of the Maternal, Child and Reproductive Health Initiative and Programme
Gemma Moncunill Assistant Research Professor
Hernando Del Portillo ICREA Research Professor
Elisa Sicuri Associate Research Professor
Regina Rabinovich Director of the Malaria Elimination Initiative

Highlighted Projects

MESA

The Malaria Eradication Scientific Alliance - MESA is dedicated to advancing the science of malaria eradication.

http://www.malariaeradication.org/

RTS,S Vaccine Immunology Study

Study of immune correlates of protection against malaria after vaccination with RTS,S/AS01E: a comprehensive immunological arm of a Phase III double-blind, randomized, controlled multi-center trial

http://www.sysmalvac.eu/